GlassScriptPhysician profile
William N Hallmon
NPI 1780603555
$3,544.30
in general payments reported to CMS, 2019-2025
25 companies · $851 in 2025
The $851 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $193 · 2021: $360 · 2022: $319 · 2023: $574 · 2024: $750 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,295.33 | 2019-2025 | |
| Janssen Biotech, INC. | $471.71 | 2019-2025 | Stelara, Tremfya, Remicade |
| Qol Medical, LLC | $390.32 | 2022-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.58 | 2019-2023 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $244.40 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $215.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $92.45 | 2021 | |
| Ardelyx, INC. | $92.27 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $90.62 | 2019-2023 | |
| Romark Laboratories, Lc | $60.20 | 2019-2020 | |
| Pfizer INC. | $48.17 | 2023 | |
| Aimmune Therapeutics, INC. | $44.34 | 2024-2025 | Zenpep |
| Boston Scientific Corporation | $39.29 | 2024-2025 | Spyglass |
| Allergan, INC. | $37.12 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $22.71 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $20.61 | 2025 | |
| Exact Sciences Corporation | $15.94 | 2024 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $15.63 | 2024 | Rebyota |
| Lilly USA, LLC | $14.82 | 2025 | Omvoh |
| Braintree Laboratories, INC. | $14.47 | 2023 | Suflave |
| Celgene Corporation | $13.68 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $13.66 | 2024 | Voquezna |
| Olympus America INC. | $13.60 | 2020 | |
| Redhill Biopharma INC. | $13.20 | 2020 | |
| Dova Pharmaceuticals | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hallmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.